High sensitivity of the Hematoflow™ solution for chronic myelomonocytic leukemia screening

Abstract

We propose a new application of the Hematoflow™ solution that can be used as a flag system for monocytosis management and CMML detection. © 2017 International Clinical Cytometry Society.

Application of immunophenotypic analysis in distinguishing chronic myelomonocytic leukemia from reactive monocytosis

“…Recent studies (16,23,24) demonstrated a significant higher percentage of the CD14+/CD16-classical monocyte subset in the peripheral blood of CMML patients (96.6%) than of age-matched healthy subjects (84%) by flow cytometry. Accumulation of CD14+/CD16-monocyte percentage ≥94% could accurately distinguish CMML from other monocytosis with a specificity of 95.1% and a sensitivity of 91.9%.…”

“…It could be improved by the use of more specific antibody panels for myeloproliferative/myelodysplastic disorders, specifically, adding progenitor cell markers CD34 and CD117 to every tube and combing HLA‐DR and CD11b with CD4, CD14, and CD64 to more closely follow monocyte maturation. Furthermore, less invasive examination of peripheral blood has shown value based on an increased fraction of CD14+/CD16‐ monocytes, which could be explored in future studies.…”

“…It could be improved by the use of more specific antibody panels Table 4 Comparison of the flow cytometry findings of CMML in bone marrow CMML (most common aberrancies) for myeloproliferative/myelodysplastic disorders, specifically, adding progenitor cell markers CD34 and CD117 to every tube and combing HLA-DR and CD11b with CD4, CD14, and CD64 to more closely follow monocyte maturation. Furthermore, less invasive examination of peripheral blood has shown value based on an increased fraction of CD14+/CD16monocytes (16,23,24), which could be explored in future studies. In summary, our data demonstrate that immunophenotypic aberrancies exist in monocytes, granulocytes, and most importantly in myeloblasts in CMML.…”

Clinical Implication of Multi-Parameter Flow Cytometry in Myelodysplastic Syndromes

“…The latter can be used as a diagnostic tool. Selimoglu-Buet et al [17] showed that using a cut-off of > 94% classical monocytes, discriminates CMML from reactive monocytosis with a specificity of 95.1% and a sensitivity of 91.9% [17][18][19][20].…”

Issue Highlights—September 2018 (94B5)

“…It has been shown recently that the accumulation of classical monocytes CD14++CD16− ≥94% in peripheral blood can help to distinguish chronic myelomonocytic leukemia (CMML) from reactive monocytosis . Vazquez et al enumerated classic monocytes by Hematoflow™ solution and found a general overestimation of the genuine classical monocyte percentages comparing to the reference method. However, due to its easy computerization and integration to the middleware, Hematoflow™ solution may be used as a flag system for patients with monocytosis.…”